In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Abstract

Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66-0.87]; however, the MIC₉₀ observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.

Keywords: Antimicrobial susceptibility testing; CRE; Carbapenem-resistant Enterobacteriaceae; Eravacycline; Tigecycline.